Samsung Bioepis' first ADC candidate wins FDA Fast Track

Samsung Bioepis said Wednesday that its first antibody-drug conjugate, or ADC, candidate has been designated a Fast Track drug by the US Food and Drug Administration. According to Samsung Bioepis, SBE303 is designed to target Nectin-4, a protein overexpressed on tumor cells. The candidate is being developed as a tre…

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.